🏥 Managed at our clinic: Our endocrinologists prescribe Evenity for high-risk osteoporosis patients in Sugar Land and Memorial City. Book a consultation →
Evenity (romosozumab) is one of the most powerful osteoporosis medications available — a monthly injectable that does something no other bone drug can: it simultaneously builds new bone AND slows bone breakdown. This dual action makes Evenity the preferred choice for patients with severe osteoporosis or those at very high fracture risk who need the fastest possible bone density gains.
❤️ Cardiovascular Caution: Evenity carries a black box warning. It should not be used in patients who have had a heart attack or stroke within the past year. Your endocrinologist will review your cardiovascular history before prescribing.
What Makes Evenity Unique: Dual Mechanism
Blocks sclerostin, unleashing osteoblasts to lay down new bone matrix. Active bone formation — not just slowing loss.
Also reduces osteoclast activity, slowing bone breakdown. The combination produces greater density gains than either effect alone.
The Evenity Treatment Course
Evenity is given for exactly 12 months — two subcutaneous injections per monthly visit (total 4 syringes over the year). After 12 months:
- The anabolic (bone-building) window closes — the drug cannot be re-administered
- Patients must transition to antiresorptive therapy (Prolia or bisphosphonate) to preserve gains
- Without follow-on therapy, bone density will decline
Clinical Results
- FRAME trial: 73% reduction in new vertebral fractures vs. placebo at 12 months; significant reduction in clinical fractures
- ARCH trial (vs. Fosamax): Evenity → Fosamax reduced vertebral fractures 48% and hip fractures 38% more than Fosamax alone
- Bone density: Spine BMD increases ~13% over 12 months — the largest gain of any osteoporosis medication
Who Is Evenity For?
- Postmenopausal women with severe osteoporosis (T-score ≤ -2.5 + prior fracture, or T-score ≤ -3.0)
- Patients who have had a vertebral fracture or are at very high 10-year fracture risk
- Patients who have failed bisphosphonate therapy
- Not for patients with heart attack or stroke in the past year
Osteoporosis Medication Comparison
| Medication | Class | How Given | Frequency | Special Notes |
|---|---|---|---|---|
| Fosamax | Bisphosphonate | Pill | Weekly | Take fasting, stay upright 30 min |
| Actonel | Bisphosphonate | Pill | Weekly/Monthly | Take fasting, stay upright 30 min |
| Reclast | Bisphosphonate | IV infusion | Once yearly | No weekly pill compliance issues |
| Prolia | RANK-L inhibitor | Injection | Every 6 months | ⚠️ NEVER miss a dose — rebound fracture risk |
| Forteo | Anabolic (PTH) | Daily injection | Daily × 2 yrs | Builds new bone; requires follow-on therapy |
| Tymlos | Anabolic (PTHrP) | Daily injection | Daily × 2 yrs | Builds new bone; requires follow-on therapy |
| Evenity | Dual-action | Monthly injection | Monthly × 12 | Builds AND protects bone; caution w/ CV history |
| Raloxifene | SERM | Daily pill | Daily | Also reduces breast cancer risk |
Frequently Asked Questions About Evenity
What is Evenity and how does it work?
Evenity (romosozumab) is a monthly injectable medication for osteoporosis, given for exactly 12 months. It is unique because it has a dual mechanism: it simultaneously builds new bone AND slows bone breakdown. It works by blocking sclerostin, a protein that inhibits bone formation. With sclerostin blocked, osteoblasts (bone-building cells) become more active, while osteoclast (bone-destroying) activity is also reduced. No other osteoporosis medication does both at the same time.
Who is Evenity for?
Evenity is FDA-approved for postmenopausal women with osteoporosis at high fracture risk — specifically those with severe osteoporosis (T-score ≤ -2.5 with a prior fracture, or T-score ≤ -3.0), multiple vertebral fractures, or those who have failed or cannot tolerate other osteoporosis medications. Due to a cardiovascular safety signal, it is not recommended in patients who have had a heart attack or stroke within the past year.
How long do you take Evenity?
Evenity is only given for 12 months — two subcutaneous injections per month (both given at the same visit, in different locations) for 12 total monthly visits. After completing 12 months of Evenity, patients must transition to an antiresorptive medication (usually Prolia or a bisphosphonate like Reclast) to preserve the bone gains achieved.
How effective is Evenity?
In the FRAME trial, Evenity reduced new vertebral fracture risk by 73% compared to placebo over 12 months. In the ARCH trial (head-to-head vs. Fosamax), Evenity followed by Fosamax reduced vertebral fractures by 48% and hip fractures by 38% compared to Fosamax alone. The dual anabolic-antiresorptive effect produces larger bone density gains than any antiresorptive alone.
Is Evenity safe for patients with heart disease?
Evenity carries a black box warning for cardiovascular risk. In the ARCH trial, there was a slightly higher rate of serious cardiovascular events (heart attack, stroke) in the Evenity group vs. alendronate. Evenity should NOT be used in patients who have had a heart attack or stroke within the past year. Patients with other cardiovascular risk factors should have the risks and benefits carefully discussed with their endocrinologist.
What happens after 12 months of Evenity?
After completing 12 months of Evenity, you must transition to an antiresorptive medication to maintain your bone density gains. Without this follow-on therapy, the bone benefits of Evenity will diminish. Most patients transition to Prolia (denosumab) or a bisphosphonate (Reclast, Fosamax). Your endocrinologist will plan this transition before your Evenity course ends.
Key Takeaways
- Evenity is the only osteoporosis medication that both builds and protects bone simultaneously
- Given monthly for exactly 12 months — must follow with antiresorptive therapy afterward
- Reduces vertebral fractures by 73% vs. placebo; 48% better than Fosamax alone in head-to-head trial
- Black box warning: not for patients with recent heart attack or stroke
- Reserved for high-risk patients — an endocrinologist evaluation is required